Director John R. Leone Named as the Company’s Lead Independent DirectorAngus Smith Promoted to Senior Vice President, Chief Business Officer and Principal Financial Officer MORRISTOWN, N.J., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty...Read More
MORRISTOWN, N.J., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that it has entered into a settlement agreement with Actavis Laboratories FL (“Actavis”) resolving patent litigation related to...Read More
Anticipated Cost Savings of $7-$8 Million MORRISTOWN, N.J., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that, due to the impending loss of exclusivity of TREXIMET® (sumatriptan and naproxen sodium...Read More
MORRISTOWN, N.J., Nov.16, 2017(GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced the election of two new directors to its Board, John R. Leone and Douglas J. Swirsky at P...Read More
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2017) - Platinex Inc. (CSE: PTX) has entered into a Letter of Intent to acquire an interest in an edible brand in the State of Oregon, that holds the rights to a brand known in the Southern and Western Oregon regions. The Letter of Intent a...Read More
MORRISTOWN, N.J., Nov.07, 2017(GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) ("Pernix" or the "Company"), a specialty pharmaceutical company, announced today financial results for the third quarter ended September 30, 2017. Third Quarter 2017 Financial Highlights:Third quart...Read More
MORRISTOWN, N.J., Nov.06, 2017(GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) ("Pernix" or the "Company"), a specialty pharmaceutical company, today announced the sale of a non-core product, Cedax (R) (ceftibuten capsules and ceftibuten for oral suspension), a third-generatio...Read More
MORRISTOWN, N.J., Oct.26, 2017(GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) ("Pernix" or the "Company"), a specialty pharmaceutical company, announced today that the Company will report financial results for the third quarter ended September 30, 2017, after the market close...Read More
MORRISTOWN, N.J., Oct.17, 2017(GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) ("Pernix" or the "Company"), a specialty pharmaceutical company, today announced that Graham Miao, Ph.D., President and Chief Financial Officer (CFO), will leave the Company at the end of the year i...Read More
MORRISTOWN, N.J., July27, 2017(GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) ("Pernix" or the "Company"), a specialty pharmaceutical company, today announced financial results for the three and six months ended June 30, 2017. Second Quarter 2017 Financial Highlights:Second q...Read More
TORONTO, ONTARIO--(Marketwired - July 25, 2017) - Platinex Inc. (CSE:PTX)(CSE:PTX.CN)(CNSX:PTX) ("Platinex" or the "Company") has engaged FMI Capital Advisory Inc. ("FMI") as financial advisor to assist in its efforts to grow, finance, secure projects, and in connection with a tr...Read More
TORONTO, ONTARIO--(Marketwired - July 21, 2017) - Platinex Inc. (CSE:PTX)(CSE:PTX.CN)(CNSX:PTX) (the "Company" or "Platinex") announces that the forty five day period set out in a Letter of Intent with Cannabee Products, Inc announced on June 7, 2017 has expired without concludin...Read More
MORRISTOWN, N.J., July20, 2017(GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) ("Pernix" or the "Company"), a specialty pharmaceutical company, today announced certain preliminary unaudited financial results for the second quarter ended June 30, 2017. Second Quarter 2017 Preli...Read More
MORRISTOWN, N.J., July20, 2017(GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) ("Pernix" or the "Company"), a specialty pharmaceutical company, today commenced a series of refinancing transactions intended to improve liquidity, extend debt maturities and enable the Company to...Read More
TORONTO, ONTARIO--(Marketwired - June 29, 2017) - Platinex Inc. (CSE:PTX)(CSE:PTX.CN)(CNSX:PTX) ("Platinex" or the "Company") announces the launch of their brand new community resource website, on Saturday, July 1st, 2017. The URL is www.cannabismall.org. The intention of the s...Read More
MORRISTOWN, N.J., June28, 2017(GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) ("Pernix" or the "Company"), announced today that it has been added to the Russell Microcap (R) index following the annual reconstitution, which took effect after the US market closed on Friday, Jun...Read More
MORRISTOWN, N.J., May15, 2017(GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) ("Pernix" or the "Company"), a specialty pharmaceutical company, today announced financial results for the three months ended March 31, 2017. First Quarter 2017 Financial Highlights:First quarter 2017...Read More
SEATTLE, WA--(Marketwired - May 25, 2017) -CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an article discussing Platinex Inc.'s (CSE: PTX) experienced team behind the launch of CannabisMall.Shop and CannabisMal...Read More
TORONTO, ONTARIO--(Marketwired - June 7, 2017) - Platinex Inc. (CSE:PTX)(CSE:PTX.CN)(CNSX:PTX) ("Platinex" or the "Company") has signed a forty five day Letter of Intent with Cannabee Products, Inc. ("Cannabee") to acquire Cannabee in a share purchase agreement. Founded in 200...Read More
TORONTO, ONTARIO--(Marketwired - Jun 19, 2017) - Platinex Inc. (CSE:PTX)(CSE:PTX.CN)(CNSX:PTX) ("Platinex" or the "Company") announces the target date of July 1st, 2017 to launch its Cannabismall.org community resource website. The Company's objective is to become a voice in the communi...Read More